Forward Ventures

Speckle is a company that provides a collaborative data hub tailored for the Architecture, Engineering, and Construction (AEC) sectors. It focuses on creating an open ecosystem that addresses the challenges of fragmentation within the industry. By offering a cloud-based platform, Speckle enables users to automate design, engineering, and construction processes. Its infrastructure includes a default set of connectors that facilitate the curation of design data and the integration of multiple data streams, allowing for advanced querying. The platform supports interoperability between different software applications, enhances real-time collaboration, and simplifies data management and versioning. This empowers clients to effectively coordinate their projects and gain valuable insights into their data footprint.

Xanadu, founded in 2016, is a company dedicated to advancing quantum computing technology, focusing on its societal implications and practical applications. The organization aims to provide quantum computing on demand, achieving significant computational enhancements beyond classical methods for complex real-world challenges. Xanadu operates a quantum photonic platform that integrates quantum silicon photonic chips with existing hardware, creating a comprehensive quantum computing solution. By combining the expertise of leading scientists with industry professionals, Xanadu seeks to develop scalable quantum technologies that are accessible to a wide range of users, enabling them to address various business problems efficiently.

Virtuoso is a technology company that specializes in developing a testing platform aimed at enhancing quality assurance through automation. The platform integrates artificial intelligence, machine learning, and robotic process automation to streamline the testing process, reducing the reliance on manual interventions. By offering codeless test automation software, Virtuoso ensures that clients can conduct functional UI testing and continuous testing efficiently, without hindering the development workflow. The platform also utilizes natural language processing to simplify quality analysis, allowing users to visualize testing journeys and obtain results in straightforward language, thus making the testing process more accessible and effective for organizations.

Viracta Therapeutics, Inc. is a clinical-stage drug development company based in Cardiff, California, that specializes in precision oncology focused on virus-associated malignancies. The company utilizes a viral activation therapy platform to develop treatments for cancers linked to the Epstein-Barr Virus (EBV) and other virus-related diseases. Its lead investigational drug, nanatinostat, is being evaluated in combination with the antiviral valganciclovir as a potential oral therapy for EBV-positive lymphoma, including post-transplant lymphoproliferative disorder, plasmablastic lymphoma, and angioimmunoblastic T cell lymphoma. Viracta is also exploring the application of this approach to other EBV-associated conditions, such as nasopharyngeal carcinoma and gastric carcinoma. Founded in 2007 and rebranded from HemaQuest Pharmaceuticals in 2015, Viracta Therapeutics is actively conducting multiple clinical trials to advance its therapeutic candidates.

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of therapies for cancer treatment. The company's lead candidate, entinostat, is a class I HDAC inhibitor currently in Phase III trials for advanced hormone receptor-positive, HER2-negative breast cancer. Additionally, Syndax is advancing SNDX-5613, a selective inhibitor targeting the Menin-MLL binding interaction, in Phase I/II trials for acute myeloid leukemia with specific mutations. The company also explores entinostat in combination with immunotherapies such as Keytruda and Tecentriq for various cancers, including non-small cell lung cancer and metastatic breast cancer. Furthermore, Syndax is developing axatilimab, a monoclonal antibody targeting the CSF-1 receptor, currently in trials for chronic graft-versus-host disease. The company maintains collaborative relationships with several major pharmaceutical entities and research organizations to enhance its drug development efforts. Founded in 2005, Syndax Pharmaceuticals is committed to advancing innovative treatments for patients with challenging malignancies.

Affinium Pharmaceuticals is a specialty pharmaceutical company dedicated to developing innovative anti-infective medications. The company focuses on its FASII antibacterial programs, which represent a new franchise of antibiotics targeting the FASII pathway. These programs are supported by a robust portfolio of intellectual property, including both issued and pending patents for potent orally available small molecule inhibitors. Affinium's unique approach aims to address the growing need for effective antibiotics by targeting an underexploited mechanism of action, positioning the company at the forefront of the fight against resistant infections.

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of therapies for cancer treatment. The company's lead candidate, entinostat, is a class I HDAC inhibitor currently in Phase III trials for advanced hormone receptor-positive, HER2-negative breast cancer. Additionally, Syndax is advancing SNDX-5613, a selective inhibitor targeting the Menin-MLL binding interaction, in Phase I/II trials for acute myeloid leukemia with specific mutations. The company also explores entinostat in combination with immunotherapies such as Keytruda and Tecentriq for various cancers, including non-small cell lung cancer and metastatic breast cancer. Furthermore, Syndax is developing axatilimab, a monoclonal antibody targeting the CSF-1 receptor, currently in trials for chronic graft-versus-host disease. The company maintains collaborative relationships with several major pharmaceutical entities and research organizations to enhance its drug development efforts. Founded in 2005, Syndax Pharmaceuticals is committed to advancing innovative treatments for patients with challenging malignancies.

Ambit Biosciences is a privately-held biopharmaceutical company that specializes in the discovery and development of small molecule kinase inhibitors aimed at treating cancer and inflammatory diseases. The company's lead compound, AC220, is a selective and orally bioavailable inhibitor of FMS-like tyrosine kinase-3 (FLT3), currently undergoing clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML). Ambit is collaborating with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors across various therapeutic areas. In addition to AC220, Ambit's clinical pipeline features AC480, a pan-HER inhibitor, and AC430, an oral inhibitor of JAK2. Furthermore, the company has several preclinical candidates, including CEP-32496, a BRAF inhibitor that is licensed to Cephalon. Through its innovative approach, Ambit aims to enhance treatment outcomes for cancer patients.

Viracta Therapeutics, Inc. is a clinical-stage drug development company based in Cardiff, California, that specializes in precision oncology focused on virus-associated malignancies. The company utilizes a viral activation therapy platform to develop treatments for cancers linked to the Epstein-Barr Virus (EBV) and other virus-related diseases. Its lead investigational drug, nanatinostat, is being evaluated in combination with the antiviral valganciclovir as a potential oral therapy for EBV-positive lymphoma, including post-transplant lymphoproliferative disorder, plasmablastic lymphoma, and angioimmunoblastic T cell lymphoma. Viracta is also exploring the application of this approach to other EBV-associated conditions, such as nasopharyngeal carcinoma and gastric carcinoma. Founded in 2007 and rebranded from HemaQuest Pharmaceuticals in 2015, Viracta Therapeutics is actively conducting multiple clinical trials to advance its therapeutic candidates.

Affinium Pharmaceuticals is a specialty pharmaceutical company dedicated to developing innovative anti-infective medications. The company focuses on its FASII antibacterial programs, which represent a new franchise of antibiotics targeting the FASII pathway. These programs are supported by a robust portfolio of intellectual property, including both issued and pending patents for potent orally available small molecule inhibitors. Affinium's unique approach aims to address the growing need for effective antibiotics by targeting an underexploited mechanism of action, positioning the company at the forefront of the fight against resistant infections.

Ambit Biosciences is a privately-held biopharmaceutical company that specializes in the discovery and development of small molecule kinase inhibitors aimed at treating cancer and inflammatory diseases. The company's lead compound, AC220, is a selective and orally bioavailable inhibitor of FMS-like tyrosine kinase-3 (FLT3), currently undergoing clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML). Ambit is collaborating with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors across various therapeutic areas. In addition to AC220, Ambit's clinical pipeline features AC480, a pan-HER inhibitor, and AC430, an oral inhibitor of JAK2. Furthermore, the company has several preclinical candidates, including CEP-32496, a BRAF inhibitor that is licensed to Cephalon. Through its innovative approach, Ambit aims to enhance treatment outcomes for cancer patients.

Nereus Pharmaceuticals, Inc. engages in the discovery and development of therapeutics for the treatment of oncology, infectious diseases, and inflammation. The company uses its marine microbiology technologies for the discovery and development of drug candidates. Its oncology drug candidates include NPI-2358, a tumor vascular disrupting agent for the treatment of solid tumors; and NPI-0052, a proteasome inhibitor for the treatment of solid tumors, lymphomas, and multiple myeloma. The company was founded in 1998 and is based in San Diego, California.

Viracta Therapeutics, Inc. is a clinical-stage drug development company based in Cardiff, California, that specializes in precision oncology focused on virus-associated malignancies. The company utilizes a viral activation therapy platform to develop treatments for cancers linked to the Epstein-Barr Virus (EBV) and other virus-related diseases. Its lead investigational drug, nanatinostat, is being evaluated in combination with the antiviral valganciclovir as a potential oral therapy for EBV-positive lymphoma, including post-transplant lymphoproliferative disorder, plasmablastic lymphoma, and angioimmunoblastic T cell lymphoma. Viracta is also exploring the application of this approach to other EBV-associated conditions, such as nasopharyngeal carcinoma and gastric carcinoma. Founded in 2007 and rebranded from HemaQuest Pharmaceuticals in 2015, Viracta Therapeutics is actively conducting multiple clinical trials to advance its therapeutic candidates.

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of therapies for cancer treatment. The company's lead candidate, entinostat, is a class I HDAC inhibitor currently in Phase III trials for advanced hormone receptor-positive, HER2-negative breast cancer. Additionally, Syndax is advancing SNDX-5613, a selective inhibitor targeting the Menin-MLL binding interaction, in Phase I/II trials for acute myeloid leukemia with specific mutations. The company also explores entinostat in combination with immunotherapies such as Keytruda and Tecentriq for various cancers, including non-small cell lung cancer and metastatic breast cancer. Furthermore, Syndax is developing axatilimab, a monoclonal antibody targeting the CSF-1 receptor, currently in trials for chronic graft-versus-host disease. The company maintains collaborative relationships with several major pharmaceutical entities and research organizations to enhance its drug development efforts. Founded in 2005, Syndax Pharmaceuticals is committed to advancing innovative treatments for patients with challenging malignancies.

Tioga Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, founded in 2005. The company is dedicated to developing innovative therapies for the treatment of pruritus and gastrointestinal diseases. Its primary product is Asimadoline, an orally active kappa opioid receptor agonist designed to alleviate itching associated with atopic dermatitis. Additionally, Tioga is focused on treating gastrointestinal conditions, with Asimadoline also aimed at addressing irritable bowel syndrome and functional dyspepsia. This drug candidate is notable for its favorable safety profile, allowing for therapeutic benefits without the typical side effects associated with mu-opioid medications.

Altair Therapeutics was a biopharmaceutical company that focused on developing therapeutics to treat human respiratory diseases.

LigoCyte Pharmaceuticals is a biotechnology company focused on developing innovative vaccines and therapeutic monoclonal antibodies aimed at treating inflammatory and infectious diseases. The company specializes in creating commercial vaccines and biodefense vaccines, with notable products including Norovirus VLP Vaccines, which mimic the live virus's surface configuration without causing infection, and an Influenza VLP Vaccine that offers protection against multiple strains, including A/H1N1 and A/H3N2. Additionally, LigoCyte is involved in the development of an anthrax vaccine and Anti-CD103 monoclonal antibodies, which play a role in the retention of activated lymphocytes at sites of inflammation. By advancing its proprietary products into human clinical testing, LigoCyte is positioned for growth in the biotechnology sector, contributing to the field of immunomodulatory drugs that target disease processes rather than merely alleviating symptoms.

Ambit Biosciences is a privately-held biopharmaceutical company that specializes in the discovery and development of small molecule kinase inhibitors aimed at treating cancer and inflammatory diseases. The company's lead compound, AC220, is a selective and orally bioavailable inhibitor of FMS-like tyrosine kinase-3 (FLT3), currently undergoing clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML). Ambit is collaborating with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors across various therapeutic areas. In addition to AC220, Ambit's clinical pipeline features AC480, a pan-HER inhibitor, and AC430, an oral inhibitor of JAK2. Furthermore, the company has several preclinical candidates, including CEP-32496, a BRAF inhibitor that is licensed to Cephalon. Through its innovative approach, Ambit aims to enhance treatment outcomes for cancer patients.

Viracta Therapeutics, Inc. is a clinical-stage drug development company based in Cardiff, California, that specializes in precision oncology focused on virus-associated malignancies. The company utilizes a viral activation therapy platform to develop treatments for cancers linked to the Epstein-Barr Virus (EBV) and other virus-related diseases. Its lead investigational drug, nanatinostat, is being evaluated in combination with the antiviral valganciclovir as a potential oral therapy for EBV-positive lymphoma, including post-transplant lymphoproliferative disorder, plasmablastic lymphoma, and angioimmunoblastic T cell lymphoma. Viracta is also exploring the application of this approach to other EBV-associated conditions, such as nasopharyngeal carcinoma and gastric carcinoma. Founded in 2007 and rebranded from HemaQuest Pharmaceuticals in 2015, Viracta Therapeutics is actively conducting multiple clinical trials to advance its therapeutic candidates.

Asteres Inc. is a San Diego-based company specializing in pharmacy automation technology, founded in 2003. The company develops and installs kiosks and lockers for the secure and efficient pickup of prescriptions and healthcare products in various settings, including retail stores, hospitals, corporate workplaces, and military bases. Its flagship product, ScriptCenter, functions similarly to an ATM, allowing consumers to collect and pay for their prescriptions at their convenience, even when pharmacies are closed or during busy hours, thereby minimizing wait times and enhancing customer experience. Asteres also offers the ScriptCenter MX kiosk for automated pickup and payment of pharmacist-filled prescriptions and a modular ScriptCenter Locker System to accommodate different prescription pickup volumes. Additionally, Asteres provides integration services for IT, pharmacy management, and payment systems, along with marketing, branding, maintenance, and support services, emphasizing customer value and service in the healthcare automation sector.

Concurrent Thinking Limited is a company based in Warwick, United Kingdom, specializing in the design and implementation of large-scale computing infrastructures and software tailored for high-performance computing. The firm offers a range of data center infrastructure management solutions, including concurrentCOMMAND, which interfaces with facilities management and IT systems to optimize energy efficiency, and concurrentCONTROL, a platform that monitors power, environmental conditions, servers, and operating systems within data centers. Additionally, Concurrent Thinking provides support and maintenance services to its clients, which include IT, environmental, and financial sectors, as well as facilities management. Established in 2009 and formerly known as Retromaze Limited, the company rebranded in June 2010 to reflect its focus on innovative system management solutions suitable for next-generation data centers.

Sequel Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes novel and clinical-stage drug candidates for patients with cardiovascular disease. The company was founded in 2007 and is based in San Diego, California.

Nereus Pharmaceuticals, Inc. engages in the discovery and development of therapeutics for the treatment of oncology, infectious diseases, and inflammation. The company uses its marine microbiology technologies for the discovery and development of drug candidates. Its oncology drug candidates include NPI-2358, a tumor vascular disrupting agent for the treatment of solid tumors; and NPI-0052, a proteasome inhibitor for the treatment of solid tumors, lymphomas, and multiple myeloma. The company was founded in 1998 and is based in San Diego, California.

TargeGen, Inc. is a biopharmaceutical company based in San Diego, California, founded in 2002. The company specializes in the discovery and development of small molecule kinase inhibitors aimed at addressing vascular leakage, vascular proliferation, and inflammation. TargeGen's products are designed for the treatment of various serious medical conditions, including heart attacks, cancer, and eye diseases. Specifically, their therapies target issues like vascular leakage, edema, unwanted growth of new blood vessels, pleural effusions, arthritis, pulmonary edema, transplant ischemia, acute respiratory distress syndrome, brain inflammation, and central nervous system disorders. The company has a particular focus on markets related to macular degeneration, diabetic macular edema, and diabetic retinopathy. In 2010, TargeGen was acquired by Sanofi Aventis.

NovaCardia is a pharmaceutical company specializing in the development of innovative treatments for cardiovascular diseases. With a strong focus on acute cardiac care, the company is dedicated to enhancing patient outcomes through the creation and commercialization of novel small molecule drugs. Among its key projects is an oral formulation of KW-3902, aimed at treating chronic congestive heart failure. NovaCardia leverages its extensive expertise in cardiovascular drug development to address critical needs in this therapeutic area.

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of therapies for cancer treatment. The company's lead candidate, entinostat, is a class I HDAC inhibitor currently in Phase III trials for advanced hormone receptor-positive, HER2-negative breast cancer. Additionally, Syndax is advancing SNDX-5613, a selective inhibitor targeting the Menin-MLL binding interaction, in Phase I/II trials for acute myeloid leukemia with specific mutations. The company also explores entinostat in combination with immunotherapies such as Keytruda and Tecentriq for various cancers, including non-small cell lung cancer and metastatic breast cancer. Furthermore, Syndax is developing axatilimab, a monoclonal antibody targeting the CSF-1 receptor, currently in trials for chronic graft-versus-host disease. The company maintains collaborative relationships with several major pharmaceutical entities and research organizations to enhance its drug development efforts. Founded in 2005, Syndax Pharmaceuticals is committed to advancing innovative treatments for patients with challenging malignancies.

Affinium Pharmaceuticals is a specialty pharmaceutical company dedicated to developing innovative anti-infective medications. The company focuses on its FASII antibacterial programs, which represent a new franchise of antibiotics targeting the FASII pathway. These programs are supported by a robust portfolio of intellectual property, including both issued and pending patents for potent orally available small molecule inhibitors. Affinium's unique approach aims to address the growing need for effective antibiotics by targeting an underexploited mechanism of action, positioning the company at the forefront of the fight against resistant infections.

Sanarus Medical, Inc. specializes in developing and marketing minimally invasive devices for the diagnosis and treatment of breast tumors. The company offers the Visica Treatment System, which utilizes cryoablation to treat breast fibroadenomas, and the Cassi II rotational core biopsy system, an automated device designed for obtaining contiguous biopsy samples. Additionally, Sanarus provides the ImarC tissue marker system, which includes breast tissue markers visible under various imaging modalities. Founded in 1999 and headquartered in Pleasanton, California, Sanarus Medical focuses on providing innovative solutions for both cancerous and non-cancerous breast conditions.

Proprius Pharmaceuticals is a San Diego-based drug developer focused on rheumatology and autoimmune diseases. The company offers two early clinical-stage therapeutic candidates comprising a product to treat pain and a product to treat rheumatoid arthritis. Proprius Pharmaceuticals was founded in 2005.

Morphotek, established in 2000, is a prominent life science company specializing in developing novel biological products to combat cancer, inflammation, and infectious diseases. The company's core technology, morphogenics, was co-invented by its current President and CEO, Dr. Nicholas Nicolaides, during his postgraduate research at Johns Hopkins Medical School. Morphotek focuses on discovering and developing monoclonal antibodies (mAbs) using this proprietary technology to treat various conditions such as ovarian and pancreatic cancers, rheumatoid arthritis, and asthma. The company conducts independent research and clinical development programs for its drug candidates.

NovaCardia is a pharmaceutical company specializing in the development of innovative treatments for cardiovascular diseases. With a strong focus on acute cardiac care, the company is dedicated to enhancing patient outcomes through the creation and commercialization of novel small molecule drugs. Among its key projects is an oral formulation of KW-3902, aimed at treating chronic congestive heart failure. NovaCardia leverages its extensive expertise in cardiovascular drug development to address critical needs in this therapeutic area.

Kémia operates as a pharmaceutical company. The company discovers and develops small molecule therapeutics. It offers allosteric kinase inhibitors for the treatment of inflammatory diseases, such as rheumatoid arthritis, as well as for cardiovascular and metabolic conditions; and modulators of G protein-coupled receptors. The company specializes in the fields of medicinal and analytical chemistry, biology, pharmacology, pharmacokinetics, pharmacodynamics, and clinical development.

Cabrellis Pharmaceuticals Corporation, a specialty pharmaceutical company developing therapies for the treatment of cancer. Cabrellis plans to initiate three separate clinical trials in small cell lung cancer (SCLC) in 2006. The first trial, designed to assess the safety and efficacy of Calsed(TM) in reference to topotecan in the second-line treatment of patients with SCLC who previously responded to platinum-based chemotherapy, is currently underway at multiple clinical trial sites in the United States.

Tioga Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, founded in 2005. The company is dedicated to developing innovative therapies for the treatment of pruritus and gastrointestinal diseases. Its primary product is Asimadoline, an orally active kappa opioid receptor agonist designed to alleviate itching associated with atopic dermatitis. Additionally, Tioga is focused on treating gastrointestinal conditions, with Asimadoline also aimed at addressing irritable bowel syndrome and functional dyspepsia. This drug candidate is notable for its favorable safety profile, allowing for therapeutic benefits without the typical side effects associated with mu-opioid medications.

Hypnion is a neuroscience drug discovery and development company based in Worcester, Massachusetts, founded in 2000. The company specializes in creating innovative therapeutics for central nervous system disorders, particularly focusing on sleep and wake-alertness disorders, as well as circadian rhythm abnormalities. Hypnion utilizes its proprietary drug discovery platform, SCORE-2004, which measures the effects of drugs on sleep and wake parameters. This unique system enables the company to advance its research and development efforts effectively. In recognition of its innovative approach and contributions to the field, Hypnion was acquired by Eli Lilly and Company.

Nereus Pharmaceuticals, Inc. engages in the discovery and development of therapeutics for the treatment of oncology, infectious diseases, and inflammation. The company uses its marine microbiology technologies for the discovery and development of drug candidates. Its oncology drug candidates include NPI-2358, a tumor vascular disrupting agent for the treatment of solid tumors; and NPI-0052, a proteasome inhibitor for the treatment of solid tumors, lymphomas, and multiple myeloma. The company was founded in 1998 and is based in San Diego, California.

TargeGen, Inc. is a biopharmaceutical company based in San Diego, California, founded in 2002. The company specializes in the discovery and development of small molecule kinase inhibitors aimed at addressing vascular leakage, vascular proliferation, and inflammation. TargeGen's products are designed for the treatment of various serious medical conditions, including heart attacks, cancer, and eye diseases. Specifically, their therapies target issues like vascular leakage, edema, unwanted growth of new blood vessels, pleural effusions, arthritis, pulmonary edema, transplant ischemia, acute respiratory distress syndrome, brain inflammation, and central nervous system disorders. The company has a particular focus on markets related to macular degeneration, diabetic macular edema, and diabetic retinopathy. In 2010, TargeGen was acquired by Sanofi Aventis.

Adiana, Inc. is a company based in Redwood City, California, founded in 1997, that focuses on the development and testing of transcervical sterilization systems for permanent birth control. The company's main product, Complete TCS, comprises a radiofrequency generator, delivery catheter, and implantable matrix, designed to occlude the fallopian tubes and prevent pregnancy. Adiana aims to provide a novel, non-incisional alternative to traditional tubal ligation, offering women a solution that minimizes the side effects and complications associated with other contraceptive methods. As of 2007, Adiana operates as a subsidiary of CYTYC Corp.

Ambit Biosciences is a privately-held biopharmaceutical company that specializes in the discovery and development of small molecule kinase inhibitors aimed at treating cancer and inflammatory diseases. The company's lead compound, AC220, is a selective and orally bioavailable inhibitor of FMS-like tyrosine kinase-3 (FLT3), currently undergoing clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML). Ambit is collaborating with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors across various therapeutic areas. In addition to AC220, Ambit's clinical pipeline features AC480, a pan-HER inhibitor, and AC430, an oral inhibitor of JAK2. Furthermore, the company has several preclinical candidates, including CEP-32496, a BRAF inhibitor that is licensed to Cephalon. Through its innovative approach, Ambit aims to enhance treatment outcomes for cancer patients.

NovaCardia is a pharmaceutical company specializing in the development of innovative treatments for cardiovascular diseases. With a strong focus on acute cardiac care, the company is dedicated to enhancing patient outcomes through the creation and commercialization of novel small molecule drugs. Among its key projects is an oral formulation of KW-3902, aimed at treating chronic congestive heart failure. NovaCardia leverages its extensive expertise in cardiovascular drug development to address critical needs in this therapeutic area.

Sanarus Medical, Inc. specializes in developing and marketing minimally invasive devices for the diagnosis and treatment of breast tumors. The company offers the Visica Treatment System, which utilizes cryoablation to treat breast fibroadenomas, and the Cassi II rotational core biopsy system, an automated device designed for obtaining contiguous biopsy samples. Additionally, Sanarus provides the ImarC tissue marker system, which includes breast tissue markers visible under various imaging modalities. Founded in 1999 and headquartered in Pleasanton, California, Sanarus Medical focuses on providing innovative solutions for both cancerous and non-cancerous breast conditions.

Predix Pharmaceuticals Holdings is a drug discovery and development company specializing in small-molecule drugs targeting G-protein coupled receptors (GPCRs) and ion channels. The company employs an innovative 3D Discovery and Optimization Engine, which includes its proprietary PREDICT algorithm for modeling the 3D structure of GPCR targets. Additionally, Predix utilizes advanced technologies such as HYPERION and RISS for high-throughput in silico screening of millions of compounds against these models. Its integrated medicinal and computational platform, ICELR-3D, aids in lead optimization by employing predictive algorithms for crucial drug properties. Predix's research focuses on developing treatments for various conditions, including anxiety, Alzheimer's disease, and pulmonary arterial hypertension. In a strategic move to enhance its capabilities, Predix merged with Physiome Sciences Inc., thereby expanding its expertise into ion channel drug discovery.

Cellective Therapeutics is a biopharmaceutical company that engages in B Cell research for cancer and autoimmune diseases. Cellective focuses on monoclonal antibodies, which, with the company's technology, can be developed so specifically that they block the root causes of autoimmunity without interfering with the body's normal response to infections.

Imagine Pharma is a biotechnology company established in 2016 and based in Pittsburgh, PA, specializing in the development of innovative therapeutic solutions. The company focuses on its proprietary IMG-1 polypeptide and has developed three distinct platforms for Oral Delivery, Therapeutics, and Regenerative Medicine. These platforms feature first-in-class programs designed to address various disease states, particularly in large and underserved markets. Imagine Pharma is actively engaged in drug discovery aimed at treating conditions such as type I and type II diabetes, cardiovascular disease, pulmonary hypertension, and related issues like cholesterol and blood pressure management. Additionally, the company has been designated as an approved Islet Isolation Center for the National Institute of Diabetes and Digestive and Kidney Diseases Integrated Islet Distribution Program, further highlighting its commitment to advancing medical treatments.

Kémia operates as a pharmaceutical company. The company discovers and develops small molecule therapeutics. It offers allosteric kinase inhibitors for the treatment of inflammatory diseases, such as rheumatoid arthritis, as well as for cardiovascular and metabolic conditions; and modulators of G protein-coupled receptors. The company specializes in the fields of medicinal and analytical chemistry, biology, pharmacology, pharmacokinetics, pharmacodynamics, and clinical development.

Morphotek, established in 2000, is a prominent life science company specializing in developing novel biological products to combat cancer, inflammation, and infectious diseases. The company's core technology, morphogenics, was co-invented by its current President and CEO, Dr. Nicholas Nicolaides, during his postgraduate research at Johns Hopkins Medical School. Morphotek focuses on discovering and developing monoclonal antibodies (mAbs) using this proprietary technology to treat various conditions such as ovarian and pancreatic cancers, rheumatoid arthritis, and asthma. The company conducts independent research and clinical development programs for its drug candidates.

TargeGen, Inc. is a biopharmaceutical company based in San Diego, California, founded in 2002. The company specializes in the discovery and development of small molecule kinase inhibitors aimed at addressing vascular leakage, vascular proliferation, and inflammation. TargeGen's products are designed for the treatment of various serious medical conditions, including heart attacks, cancer, and eye diseases. Specifically, their therapies target issues like vascular leakage, edema, unwanted growth of new blood vessels, pleural effusions, arthritis, pulmonary edema, transplant ischemia, acute respiratory distress syndrome, brain inflammation, and central nervous system disorders. The company has a particular focus on markets related to macular degeneration, diabetic macular edema, and diabetic retinopathy. In 2010, TargeGen was acquired by Sanofi Aventis.

Sanarus Medical, Inc. specializes in developing and marketing minimally invasive devices for the diagnosis and treatment of breast tumors. The company offers the Visica Treatment System, which utilizes cryoablation to treat breast fibroadenomas, and the Cassi II rotational core biopsy system, an automated device designed for obtaining contiguous biopsy samples. Additionally, Sanarus provides the ImarC tissue marker system, which includes breast tissue markers visible under various imaging modalities. Founded in 1999 and headquartered in Pleasanton, California, Sanarus Medical focuses on providing innovative solutions for both cancerous and non-cancerous breast conditions.

Conforma Therapeutics Corporation designs and develops drugs for the treatment of cancer. It develops drugs that induce tumor cells to degrade the proteins that promote cancer growth. The company offers HSP90 and CNF1010 which are used for the treatment of cancer. The company was incorporated in 1999 and is based in San Diego, California

NovaCardia is a pharmaceutical company specializing in the development of innovative treatments for cardiovascular diseases. With a strong focus on acute cardiac care, the company is dedicated to enhancing patient outcomes through the creation and commercialization of novel small molecule drugs. Among its key projects is an oral formulation of KW-3902, aimed at treating chronic congestive heart failure. NovaCardia leverages its extensive expertise in cardiovascular drug development to address critical needs in this therapeutic area.

Micromet is a biotechnology company focused on the research, development and commercialization of novel biological products for the treatment and control of cancer. Their lead product candidate, Canvaxin, is one of a new class of products being developed in the area of specific active immunotherapy, also known as therapeutic cancer vaccines.

Acorda Therapeutics is a biopharmaceutical company focused on developing and commercializing therapies for neurological disorders. Founded in 1995 and headquartered in Ardsley, New York, the company markets Ampyra (dalfampridine), an oral drug approved by the FDA to improve walking in patients with multiple sclerosis (MS). In Europe, this drug is marketed as Fampyra. Acorda also markets Selincro for alcohol dependence in Europe and Zanaflex Capsules for spasticity management. Additionally, the company develops Inbrija for treating OFF periods in Parkinson’s disease and ARCUS for acute migraine. Other pipeline products include rHIgM22 for MS and Cimaglermin alfa for heart failure. Acorda has collaborations with Biogen Inc. for Ampyra's development and commercialization.

Hypnion is a neuroscience drug discovery and development company based in Worcester, Massachusetts, founded in 2000. The company specializes in creating innovative therapeutics for central nervous system disorders, particularly focusing on sleep and wake-alertness disorders, as well as circadian rhythm abnormalities. Hypnion utilizes its proprietary drug discovery platform, SCORE-2004, which measures the effects of drugs on sleep and wake parameters. This unique system enables the company to advance its research and development efforts effectively. In recognition of its innovative approach and contributions to the field, Hypnion was acquired by Eli Lilly and Company.

Kémia operates as a pharmaceutical company. The company discovers and develops small molecule therapeutics. It offers allosteric kinase inhibitors for the treatment of inflammatory diseases, such as rheumatoid arthritis, as well as for cardiovascular and metabolic conditions; and modulators of G protein-coupled receptors. The company specializes in the fields of medicinal and analytical chemistry, biology, pharmacology, pharmacokinetics, pharmacodynamics, and clinical development.

TargeGen, Inc. is a biopharmaceutical company based in San Diego, California, founded in 2002. The company specializes in the discovery and development of small molecule kinase inhibitors aimed at addressing vascular leakage, vascular proliferation, and inflammation. TargeGen's products are designed for the treatment of various serious medical conditions, including heart attacks, cancer, and eye diseases. Specifically, their therapies target issues like vascular leakage, edema, unwanted growth of new blood vessels, pleural effusions, arthritis, pulmonary edema, transplant ischemia, acute respiratory distress syndrome, brain inflammation, and central nervous system disorders. The company has a particular focus on markets related to macular degeneration, diabetic macular edema, and diabetic retinopathy. In 2010, TargeGen was acquired by Sanofi Aventis.

Dynavax Technologies Corporation is a biopharmaceutical company specializing in the development and commercialization of innovative vaccines. Its flagship product, HEPLISAV-B, is a recombinant adjuvanted hepatitis B vaccine approved for use in adults aged 18 years and older, targeting all known subtypes of the hepatitis B virus. The company utilizes its proprietary Toll-like Receptor Immune Modulation Platform to enhance both innate and adaptive immune responses. Dynavax is actively advancing its immuno-oncology portfolio and has several development-stage products, including SD-101 and DV281, aimed at various cancer indications. In addition, the company engages in multiple research collaborations to develop adjuvanted vaccines for infectious diseases, including COVID-19, partnering with organizations such as Clover Biopharmaceuticals, the University of Queensland, and the Coalition for Epidemic Preparedness Innovations. Established in 1996 and headquartered in Emeryville, California, Dynavax continues to expand its role in vaccine development.

Micromet is a biotechnology company focused on the research, development and commercialization of novel biological products for the treatment and control of cancer. Their lead product candidate, Canvaxin, is one of a new class of products being developed in the area of specific active immunotherapy, also known as therapeutic cancer vaccines.

Gryphon Therapeutics is a biopharmaceutical company focused on the development of performance-enhanced protein therapeutics. Its products combine chemically synthesized protein backbones with polyethylene glycols such as molecules to create potent medications.

Sanarus Medical, Inc. specializes in developing and marketing minimally invasive devices for the diagnosis and treatment of breast tumors. The company offers the Visica Treatment System, which utilizes cryoablation to treat breast fibroadenomas, and the Cassi II rotational core biopsy system, an automated device designed for obtaining contiguous biopsy samples. Additionally, Sanarus provides the ImarC tissue marker system, which includes breast tissue markers visible under various imaging modalities. Founded in 1999 and headquartered in Pleasanton, California, Sanarus Medical focuses on providing innovative solutions for both cancerous and non-cancerous breast conditions.

AGY Therapeutics is a biopharmaceutical company based in South San Francisco, California, founded in 1998. The company specializes in discovering, developing, and commercializing treatments for diseases of the central nervous system (CNS). Its focus areas include neurodegenerative diseases, CNS injuries, stroke, cognitive diseases, and schizophrenia. AGY Therapeutics has a pipeline of novel therapeutic programs, both in clinical and preclinical development, aimed at addressing significant unmet medical needs. The company uses its proprietary platform for functional gene discovery and mapping specific pathways underlying CNS diseases to identify potential target proteins that can modulate disease progression. This approach is designed to pave the way for innovative CNS therapeutics.

Acorda Therapeutics is a biopharmaceutical company focused on developing and commercializing therapies for neurological disorders. Founded in 1995 and headquartered in Ardsley, New York, the company markets Ampyra (dalfampridine), an oral drug approved by the FDA to improve walking in patients with multiple sclerosis (MS). In Europe, this drug is marketed as Fampyra. Acorda also markets Selincro for alcohol dependence in Europe and Zanaflex Capsules for spasticity management. Additionally, the company develops Inbrija for treating OFF periods in Parkinson’s disease and ARCUS for acute migraine. Other pipeline products include rHIgM22 for MS and Cimaglermin alfa for heart failure. Acorda has collaborations with Biogen Inc. for Ampyra's development and commercialization.

Ambit Biosciences is a privately-held biopharmaceutical company that specializes in the discovery and development of small molecule kinase inhibitors aimed at treating cancer and inflammatory diseases. The company's lead compound, AC220, is a selective and orally bioavailable inhibitor of FMS-like tyrosine kinase-3 (FLT3), currently undergoing clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML). Ambit is collaborating with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors across various therapeutic areas. In addition to AC220, Ambit's clinical pipeline features AC480, a pan-HER inhibitor, and AC430, an oral inhibitor of JAK2. Furthermore, the company has several preclinical candidates, including CEP-32496, a BRAF inhibitor that is licensed to Cephalon. Through its innovative approach, Ambit aims to enhance treatment outcomes for cancer patients.

Variagenics is a biotechnology company that focuses on the development and commercialization of proprietary gene variance detection technology. This technology is designed to enhance and streamline the drug development process. In addition to its core activities in gene variance detection, Variagenics is involved in the manufacturing and development of molecular diagnostic products. The company serves clients primarily in the United States, offering innovative solutions aimed at improving drug discovery and diagnostic accuracy. Through its advancements in genetic diagnostics, Variagenics plays a significant role in the evolving landscape of personalized medicine.

Corixa was a developer of immunotherapeutics founded in 1994, dedicated to treating and preventing autoimmune diseases, cancer, and infectious diseases by understanding and directing the immune system. The company engaged in various preclinical development programs, including BEXXAR® therapy and MELACINE® vaccine. Corixa focused on immunotherapeutic products, possessing a broad technology platform that facilitated integrated vaccine design and the use of proprietary product components independently. The company established partnerships with numerous pharmaceutical developers and marketers to enhance the availability of its products. In July 2005, Corixa was acquired by GlaxoSmithKline, which utilized Corixa's MPL adjuvant in some of its vaccines. However, Corixa ultimately ceased operations in March 2006.